Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for preventing and treating diabetes and hyperlipemia and application thereof in drug preparation

A technology for hyperlipidemia and diabetes, applied in the field of medicine, can solve problems such as unreported pharmacological effects

Active Publication Date: 2017-06-13
KUNMING INST OF BOTANY - CHINESE ACAD OF SCI +1
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no report about the pharmacological effects of borapetoside E in treating diabetes and hyperlipidemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for preventing and treating diabetes and hyperlipemia and application thereof in drug preparation
  • Drug for preventing and treating diabetes and hyperlipemia and application thereof in drug preparation
  • Drug for preventing and treating diabetes and hyperlipemia and application thereof in drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Tinospora chinensis was collected in Simao, Yunnan in 2012, with a dry weight of 15 kg, crushed, and extracted three times with 95% ethanol at room temperature by cold soaking (25 liters each time), for 5 days each time. Recover and concentrate under reduced pressure to obtain 1100 g of the extract, which was subjected to silica gel column chromatography and eluted with petroleum ether / acetone mixed solvent gradient (99:1 to 0:100) to obtain 7 components A-G. Component E (180 g) was subjected to silica gel column chromatography and eluted with a gradient of chloroform / methanol mixed solvent (40:1 to 5:1) to obtain three components E1-E3. Component E1 was repeatedly chromatographed on a Sephadex LH-20 column and eluted with methanol to obtain 5.3 g of pure compound borapetoside E. Identification of compound structures was confirmed by comparison and interpretation of spectral data.

[0027] 1. Effect of Borapetoside E on high-fat diet (HFD)-induced hyperglycemia in mice...

Embodiment 2

[0053] Preparation of health food:

[0054] Take 15.5 mg of borapetoside E, add 200 mg of starch, 66.6 mg of lactose, 1 mg of menthol, and 50.6 mg of sodium carboxymethyl starch to make lozenges as a health food.

Embodiment 3

[0056] Preparation of injection preparations:

[0057] According to the method of Example 1, 50 mg of the compound borapetoside E of the present invention was first obtained, which was dissolved in 2 milliliters of propylene glycol, and the resulting solution was filtered and packed into ampoules under aseptic conditions.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new application of borapetoside E for preventing and treating diabetes and hyperlipemia. A research discovers that a compound borapetoside E is capable of obviously reducing the level of blood sugar and blood lipid of HFD (High Fat Diet) induced mice and improving insulin sensitivity of the HFD induced mice. The hypoglycemic and anti-hyperlipidemic effects of 40mg / kg of the compound borapetoside E are superior to those of 200mg / kg of metformin. In addition, the duration time of the hypoglycemic effect is longer than that of 200mg / kg of the metformin, the hypoglycemic effect after drug discontinuance of single drug administration of 40mg / kg of the compound borapetoside E continues for 36 hours, and the duration time after the drug discontinuance of five times of drug administration continues for 4 days. The borapetoside E under the therapeutic dosage has no toxic and side effects, the serum glutamic pyruvic transaminase level is remarkably reduced after successive administration is carried out on the mice for 16 days, serum glutamic oxalacetic transaminase, creatine kinase and creatinine are not obviously changed, and the borapetoside E can be used for preparing drugs, healthcare products and functional food for preventing and treating the diabetes.

Description

[0001] Technical field: [0002] The invention relates to a compound borapetoside E and a new application of a drug combination using the compound as an active ingredient in the prevention and treatment of diabetes and hyperlipidemia, belonging to the technical field of medicine. [0003] technical background: [0004] According to estimates by the International Diabetes Federation, in 2013, there were 380 million people with diabetes worldwide, and more than 90% of them had type 2 diabetes. The main symptoms of type 2 diabetes are hyperglycemia, hyperlipidemia, and insulin resistance, which are also the main causes of cataracts, infections, fatty liver, cardiovascular disease, diabetic foot, and even death. Diabetes has seriously affected people's quality of life and caused a lot of medical expenses. Therefore, in addition to exercise and diet control, finding drugs for treating diabetes is still a hot spot in current pharmaceutical research. [0005] Tinospora persicae belo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P3/06A61P3/10A23L33/105A23L33/125
CPCA23V2002/00A61K31/7048A23V2200/328A23V2250/21A23V2250/60
Inventor 熊文勇刘吉开许宇辉牛艳芬胡敬
Owner KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com